Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Kinase, a-subunit

Liver phosphorylase kinase a subunit Glycogen synthase... [Pg.247]

Visconti, P.E., Moore, G.D., Bailey, J.L., Leclerc, P., Connors, S.A., Pan, D., Olds-Clarke, P., and Kopf, G.S. (1995b). Capacitation of mouse spermatozoa. 11. Protein tyrosine phosphorylation and capacitation are regulated by a cAMP-dependent pathway. Development I21 1139-1150. Visconti, P.E., Johnson, L., Oyaski, M., Pomes, M., Moss, S.B., Gerton, G.L., and Kopf. G.S. (1997). Regulation, localization, and anchoring of protein kinase A subunits during mouse sperm capacitation. Dev. Biol. 792 351-363. [Pg.107]

Fig. 20.16. Regulation of pyruvate dehydrogenase complex (PDC). PDC kinase, a subunit of the enzyme, phosphorylates PDC at a specific serine residue, thereby converting PDC to an inactive form. The kinase is inhibited by ADP and pyruvate. PDC phosphatase, another subunit of the enzyme, removes the phosphate, thereby activating PDC. The phosphatase is activated by Ca ". When the substrates, pyruvate and CoASH, are bound to PDC, the kinase activity is inhibited and PDC is active. When the products acetyl CoA and NADH bind to PDC, the kinase activity is stimulated, and the enzyme is phosphorylated to the inactive form. E] and the kinase exist as tissue-specific isozymes with overlapping tissue spiecificity, and somewhat different regulatory properties. Fig. 20.16. Regulation of pyruvate dehydrogenase complex (PDC). PDC kinase, a subunit of the enzyme, phosphorylates PDC at a specific serine residue, thereby converting PDC to an inactive form. The kinase is inhibited by ADP and pyruvate. PDC phosphatase, another subunit of the enzyme, removes the phosphate, thereby activating PDC. The phosphatase is activated by Ca ". When the substrates, pyruvate and CoASH, are bound to PDC, the kinase activity is inhibited and PDC is active. When the products acetyl CoA and NADH bind to PDC, the kinase activity is stimulated, and the enzyme is phosphorylated to the inactive form. E] and the kinase exist as tissue-specific isozymes with overlapping tissue spiecificity, and somewhat different regulatory properties.
GSD 9 (GSD 8 by McKuskk) Liver phosphorylase kinase, a-subunit Xp22.2-p22,l 306000... [Pg.337]

Myristic acid may be linked via an amide bond to the a-amino group of the N-terminal glycine residue of selected proteins (Figure 9.18). The reaction is referred to as A -myristoylation and is catalyzed by myristoyl—CoAtprolein N-myris-toyltransferase, known simply as NMT. A -Myristoyl-anchored proteins include the catalytic subunit of cAMP-dependent protein kinase, the ppSff tyrosine kinase, the phosphatase known as calcineurin B, the a-subunit of G proteins (involved in GTP-dependent transmembrane signaling events), and the gag proteins of certain retroviruses, including the FHV-l virus that causes AIDS. [Pg.275]

FIGURE 2.7 Production of second messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) through activation of the enzyme phospholipase C. This enzyme is activated by the a- subunit of Gq-protein and also by Py subunits of Gj-protein. IP3 stimulates the release of Ca2+ from intracellular stores while DAG is a potent activator of protein kinase C. [Pg.25]

AMP-activated protein kinases are heterotrimeric complexes comprised of catalytic a subunits and regulatory (3 and y subunits (Table 1). Each subunit is encoded by at least two genes, some of which can also be subject to alternate splicing, leading to a diverse array of possible heterotrimeric combinations. [Pg.69]

The a subunits, for which two isoforms exist in mammals (al, a2), contain conventional protein serine/threonine kinase domains at the N-terminus, with a threonine residue in the activation loop (Thr-172) that must be phosphorylated by upstream kinases (see below) before the kinase is active. The kinase domain is followed by an autoinhibitory domain, whose effect is somehow relieved by interaction with the other subunits. The C-terminal domain of the a subunit is required for the formation of a complex with the C-terminal domain of the (3 subunit, which in turn mediates binding to the y subunit. The al and a2 catalytic subunit isoforms are widely distributed, although a2 is most abundant in muscle and may be absent in cells of the endothelial/hemopoietic lineage. [Pg.69]

Insulin Receptor. Figure 1 Structure and function of the insulin receptor. Binding of insulin to the a-subunits (yellow) leads to activation of the intracellular tyrosine kinase ((3-subunit) by autophosphorylation. The insulin receptor substrates (IRS) bind via a phospho-tyrosine binding domain to phosphorylated tyrosine residues in the juxtamembrane domain of the (3-subunit. The receptor tyrosine kinase then phosphorylates specific tyrosine motifs (YMxM) within the IRS. These tyrosine phosphorylated motifs serve as docking sites for some adaptor proteins with SRC homology 2 (SH2) domains like the regulatory subunit of PI 3-kinase. [Pg.632]

S-acylated proteins include many GTP-binding regulatory proteins (G proteins), including most a subunits of heterotrimeric G-proteins and also many members of the Ras superfamily of monomeric G proteins, a number of G protein-coupled receptors, several nonreceptor tyrosine kinases, and a number of other signaling molecules, -acylation is posttranslational and reversible, a property that allows the cell to control... [Pg.691]

Protein kinase A (PKA) is a cyclic AMP-dependent protein kinase, a member of a family of protein kinases that are activated by binding of cAMP to their two regulatory subunits, which results in the release of two active catalytic subunits. Targets of PKA include L-type calcium channels (the relevant subunit and site of phosphorylation is still uncertain), phospholam-ban (the regulator of the sarcoplasmic calcium ATPase, SERCA) and key enzymes of glucose and lipid metabolism. [Pg.979]

The antisense oligonucleotide LErafAON against the serine/threonine kinase c-Raf has been tested in phase I clinical trials. The antisense oligonucleotides ISIS-5132, which also inhibits c-Raf, and ISIS-3521, which inhibits PKC, went through different phase clinical trials with solid tumour patients. Unfortunately, no objective responses occurred with these PKI. GEM-231, an oligonucleotide targeting the RIa subunit of protein kinase A is currently undergoing phase I/II clinical trials alone or in combination with traditional therapy for the treatment of solid cancers [3]. [Pg.1011]


See other pages where Kinase, a-subunit is mentioned: [Pg.637]    [Pg.576]    [Pg.576]    [Pg.6721]    [Pg.637]    [Pg.576]    [Pg.576]    [Pg.6721]    [Pg.278]    [Pg.546]    [Pg.24]    [Pg.83]    [Pg.2]    [Pg.71]    [Pg.71]    [Pg.71]    [Pg.216]    [Pg.478]    [Pg.633]    [Pg.675]    [Pg.692]    [Pg.707]    [Pg.815]    [Pg.817]    [Pg.844]    [Pg.1213]    [Pg.1237]    [Pg.1238]    [Pg.1308]    [Pg.174]    [Pg.191]    [Pg.436]    [Pg.460]    [Pg.462]    [Pg.462]    [Pg.10]    [Pg.12]    [Pg.30]    [Pg.329]    [Pg.329]    [Pg.323]   
See also in sourсe #XX -- [ Pg.337 ]




SEARCH



A, subunit

A-kinase

© 2024 chempedia.info